Search PubMed⌕ Search

Biomedical subjects

H Busch

Publications and source records attributed to H Busch.

At least 55 records · Page 3Linked to original sources
PubMed1989

Nucleologenesis: use of non-isotopic in situ hybridization and immunocytochemistry to compare the localization of rDNA and nucleolar proteins during mitosis.

Using in situ hybridization and immunocytochemistry during interphase and mitosis, we have compared the distribution of ribosomal DNA (rDNA) to that of the nucleolar proteins fibrillarin and RNA polymerase I. During interphase, nucleolar proteins were localized at sites throughout the nucleolus while the bulk of rDNA was localized in a single restricted nucleolar area. During metaphase and anaphase, all six NORs were detected by in situ hybridization, Ag-staining, or by the immunolocalization of RNA polymerase I. During telophase, rDNA and RNA polymerase I were found in a distinct subset of the prenucleolar bodies (PNBs) which obviously must contain the nucleolar organizers. Other numerous PNBs are smaller in size and do not contain detectable amounts of rDNA or RNA polymerase I. Therefore, reconstruction of the nucleolus originates in telophase-specific domains which contain both rDNA and RNA polymerase I.

Animals↗
PubMed1989

Simultaneous immunoelectron microscopic visualization of protein B23 and C23 distribution in the HeLa cell nucleolus.

The intranucleolar distribution of phosphoproteins B23 and C23 was visualized simultaneously by post-embedding immunoelectron microscopy in HeLa cell nucleoli, using specific antibodies. The data show that proteins B23 and C23 co-localize to the same nucleolar compartments, i.e., the dense fibrillar component and the granular component. Neither of the two antibodies is significantly associated with the fibrillar centers in these cells, although the fibrillar centers appear positive after silver staining. These findings suggest that other unidentified components must be responsible for the silver staining observed in the fibrillar centers of interphase nucleoli. The results are discussed in the light of previously reported data obtained by preembedding immunolabeling techniques and by silver staining, which both suggested a localization of protein C23 inside the fibrillar centers.

Antibodies, Monoclonal↗
PubMed1989

Proliferation-related nucleolar antigens P145 and P120 associated with separate nucleolar elements and differences in tissue distribution.

Nucleolar antigens p145 and p120 are associated with proliferating cells (Freeman, J.W.; McRorie, D.K.; Busch, R.K.; Gyorkey, P.; Gyorkey, F.; Ross, B.E.; Spohn, W.H.; Busch, H. Cancer Res. 46:3593; 1986 and Freeman, J.W.; Busch, R.K.; Gyorkey, P.; Gyorkey, F.; Ross, B.E.; Busch, H. Cancer Res. 48:1244; 1988) and are not detectable in normal resting cells. Recent immunoelectron microscopic studies (Ochs, R.L.; Reilly, M.T.; Freeman, J.W.; Busch, H. Cancer Res. 48:6523; 1988) suggest that the two antigens have overlapping nucleolar localizations. In this study the nucleolus was physicochemically and biochemically studied to determine whether p145 and p120 were associated with a common nucleolar component. Antigen p145 was associated with 40-80 S ribonucleoprotein particles (RNPs), and the p145 antigen was not detected in HeLa cells following in situ RNAse digestion. P120 was found in a 40-80 S, RNAse resistant complex. Sequential extraction of HeLa nucleoli showed that most of antigen p145 was extractable in 10 mM Tris with 0.2% deoxycholate, whereas p120 was found in a nucleolar residue fraction requiring DNAse and high salt treatment for optimal extraction. Neither antigen p145 nor p120 was detectable in normal resting tissues. Antigen p145 was detected in all proliferating tissues examined, including a variety of malignant tumors (ten of ten), benign tissues including adenomas and hyperplasias (eight of eight), and in normal proliferating cells such as colonic epithelium and spermatogonia of the testes. Antigen p120 was not detected in all tumors, being absent in three of seven lymphomas and in one melanoma examined.(ABSTRACT TRUNCATED AT 250 WORDS)

Antigens, Nuclear↗
PubMed1989

mRNA levels for human nucleolar protein P120 in tumor and nontumor cells.

A monoclonal antibody to a human tumor nucleolar 120 kD protein was developed by Freeman et al. (Cancer Res. 48: 1244-1251, 1988). Its complementary DNA (cDNA) has been isolated and sequenced (Fonagy et al., submitted). To determine the relative messenger RNA (mRNA) level for protein p120, cellular mRNA was extracted, slot-blotted onto nitrocellulose filters, and hybridized to radioactive p120 cDNA fragments. Human tumor cells contained 15-60 times more p120 mRNA than human term placenta. The rat Novikoff hepatoma ascites cell mRNA hybridized to the p120 cDNA probes, but the p120 monoclonal antibody did not react with the Novikoff hepatoma proteins. Novikoff hepatoma mRNA contained 8 times as much p120 mRNA as normal rat liver. As a control, a cDNA was used for protein B23, an abundant nucleolar protein; there were 3.5, 29, and 14 times more B23 mRNA than p120 mRNA in normal rat liver, Novikoff hepatoma ascites cells, and HeLa cells, respectively. Whereas the increased levels of the mRNA and protein B23 reflect increased activity of the nucleolus for any increment of nucleolar function, the increased levels of p120 mRNA and the p120 protein reflect the activity of the G1 phase of the cell cycle. The elevated level of p120 mRNA in tumors may reflect the heightened G1 cascade in transformed cells.

Animals↗
PubMed1989

Cloning of the cDNA and sequence of the human proliferating-cell nucleolar protein P120.

The 120 kDa proliferating-cell nucleolar antigen described by Freeman et al. (Cancer Res. 48:1244; 1988) is the most cancer specific of the proliferation-associated nucleolar proteins identified thus far. It is localized in a novel nucleolar microfibrillar structure recently described by Ochs et al. (Cancer Res. 48:6523; 1988). The amino acid sequence has been determined by a combination of cDNA and genomic DNA sequences. This molecule contains, consecutively, four major domains: a basic domain, an acidic domain, a hydrophobic and methionine-rich domain, and a domain rich in cysteine and proline residues. The isolated cDNA was shown to code for the HeLa P120 protein as shown by a similarity in immunoreactivity, mobility on sodium dodecylsulfate-polyacrylamide gel electrophoresis, and patterns of partial digestion of the Escherichia coli-expressed P120 and the HeLa nucleolar P120 protein. This protein is of special interest because it is expressed in early G1 and, in studies to date, it has not been detected in benign tumors and most normal resting tissues.

Amino Acid Sequence↗
PubMed1988

Characterization of a nuclear antigen (Mr 150,000) associated with cell proliferation.

In the course of development of a "library" of monoclonal antibodies to nucleolar proteins, a monoclonal antibody to a nuclear antigen with a molecular weight of 150,000 was obtained. Using this monoclonal antibody as an immunocytochemical probe, low immunofluorescence was demonstrated in human peripheral blood lymphocytes or HL-60 cells treated with retinoic acid. In contrast, a high degree of immunofluorescence was detected in rapidly proliferating human cells (HeLa, Hep-2, HL-60), in Novikoff hepatoma cells, and in phytohemagglutinin-activated human blood lymphocytes. Immunodot blot analysis indicated there were low levels of Mr 150,000 protein in quiescent lymphocytes and increasing amounts after stimulation with phytohemagglutinin. The increased level of Mr 150,000 protein thus is associated with cell proliferation.

Animals↗
PubMed1988

Intranucleolar localization of human proliferating cell nucleolar antigen p120.

The human proliferation-associated nucleolar antigen p120 was localized to substructures within HeLa cell nucleoli by immunofluorescence and immunoelectron microscopy of cells whose nucleoli were segregated by drug treatment or extracted with nucleases. By indirect immunofluorescence, protein p120 was localized diffusely throughout all interphase nucleoli. However, high resolution immunoelectron microscopy demonstrated that protein p120 staining delineated a network of 20-30-nm diameter beaded fibrils distributed throughout the nucleolus. This distribution was unique compared to that of the nucleolar proteins p145, RNA polymerase I, or B23 which were examined simultaneously. Drug-induced segregation of nucleoli by actinomycin D or dichlorobenzimidazole riboside, followed by immunoelectron microscopy, indicated that protein p120 was concentrated at the periphery of the granular region in segregated nucleoli. In situ nuclease digestion of cells with DNase I and/or RNase A did not release p120 from the nucleolus. Instead, p120 immunoreactivity was retained within phase-dense residual nucleoli. These results provide evidence that protein p120 is associated with, and in fact delineates, a network of fibrils which is retained in the nucleolar residue fraction of proliferating cells.

Antigens, Neoplasm↗
PubMed1988

Optimal loading of scraped HeLa cells with monoclonal antibodies to the proliferation-associated Mr 120,000 nucleolar antigen.

Our laboratory has reported (J. W. Freeman et al., Cancer Res., 48:1244-1251, 1988) a proliferation-associated Mr 120,000 nucleolar antigen (p120), that was found in human tumors but was not detectable in most normal resting tissues and in benign tumors. To study further the function and the localization of this protein, we have investigated various methods of microinjecting p120 monoclonal antibodies into cells. For comparison, we have used a monoclonal antibody to protein C23, a nucleolar protein found in high levels in most cells. To determine optimal conditions for loading of antibodies to nucleolar antigens into mechanically disrupted HeLa cells, we studied the effects of ionic strengths of loading buffers, various antibody concentrations, and optimal time for loading and antibody localization. With ascites fluids in isotonic buffer containing antibodies to nucleolar proteins p120 and C23, a maximum number of cells, 86 and 84%, respectively, were loaded following a 20-min incubation. Hypotonic buffers decreased the percentage of cells loaded (22%); hypertonic buffers reduced cell viability. The optimal concentration of purified antibody yielding a maximum number of loaded cells (81%) was 2.5 mg/ml. Higher concentrations of antibody resulted in residual cytoplasmic staining without increasing the percentage of loaded cells. With antibody concentrations less than 2.5 mg/ml, a linear decrease was noted in the percentage of cells loaded with a decrease in intensity of fluorescence. Following antibody loading, nucleolar fluorescence was observed by 12 h and the intensity increased at 24 h. Localization of the p120 antibody was followed through mitosis where it was perichromosomal and equally divided between the chromosomes at metaphase. A decrease of nucleolar immunofluorescence intensity and percentage of cells labeled were observed in successive cell generations.

Antibodies, Monoclonal↗
PubMed1988

Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase.

Tumor nucleoli were treated with polyclonal antisera to normal human tissue nucleoli to block some determinants common to tumor and normal tissue nucleoli. Immunization of mice with these immune complexes resulted in the development of a monoclonal antibody (FB2) to a novel Mr 120,000 nucleolar proliferation-associated antigen. By indirect immunofluorescence, antibody FB2 produced bright nucleolar staining in a variety of malignant tumors, including cancers of the breast, liver, gastrointestinal tract, genitourinary tract, blood, lymph system, lung, and brain. Although specific nucleolar immunofluorescence was not detectable in most normal tissues, it was detectable in some proliferating nonmalignant tissues including spermatogonia of the testes, ductal regions of hypertrophied prostates, and phytohemagglutinin-stimulated lymphocytes. The Mr 120,000 antigen was not detectable in 48-h serum-deprived HeLa cells but was readily detectable (within 30 min) following serum refeeding. The Mr 120,000 antigen was not detected in retinoic acid-treated HL-60 cells following morphological differentiation but was detectable in 48-h phytohemagglutinin-treated lymphocytes. These studies suggest that the Mr 120,000 antigen is a proliferation-associated antigen which plays a role in the early G1 phase of the cell cycle.

Antibodies, Monoclonal↗
PubMed1988

Pharmacotherapy of alcohol-withdrawal syndrome in hospitalised patients. Clinical and methodological aspects.

Because of the unreliability of the alcoholic, these suggestions are only intended for inpatients. Effective agents are presented first, and then the often very different pharmacological concepts are critically reviewed. Physicians use target symptoms as checkpoints for the effective pharmacological treatment of the alcohol-withdrawal syndrome. Clomethiazole and benzodiazepines are regarded as proven monotherapeutics against delirium. However, their somatic side effects and above all the problems of drug dependence make it necessary to look for a lower-risk medication. In every case, physicians must look more closely into the possibility of treating the individual alcohol-withdrawal syndrome with an agent less liable to cause addiction. Attractive, adequately tested alternatives are now becoming available for the large number of withdrawal syndromes which are below the level of delirium in terms of severity. This paper discusses the significance of substances without dependence potential, e.g. carbamazepine. This aspect is of special interest for the psychiatrist, whose task it is to guarantee the patient's abstinence after detoxification. We also look at other possible advantages of these substances when given in combination with drugs of the alcohol-barbiturate group against severe alcohol-withdrawal syndromes. Following a discussion of priority questions for further research, we draw attention to methodological deficiencies in earlier evaluation studies, and make suggestions for improved designs of drug trials.

Alcoholism↗
PubMed1987

Identification and partial characterization of a Mr 105,000 nucleolar antigen associated with cell proliferation.

This study reports the identification and partial characterization of a novel Mr 105,000 nucleolar antigen (P105) identified by a monoclonal antibody. This monoclonal antibody was obtained when a nucleolar protein extract separated from the immunodominant protein C23 was used as the immunogen. Nucleolar antigen P105 was not detected in normal (resting) human liver, kidney, or peripheral blood lymphocytes but was present in a variety of human malignant cells and tissues. Lymphocyte nucleoli also exhibited specific P105 staining after 72 h of phytohemagglutinin stimulation. Nucleolar antigen P105 was detected in growing and dividing HL 60 cells but was not detected in retinoic acid-induced differentiated HL 60 cells. When HeLa cells were made quiescent by 48 h of serum starvation, the P105 antigen was not detected, but after refeeding with serum-containing medium, the antigen P105 was detected in the HeLa nucleoli within 2 h. These results indicate that nucleolar antigen P105 is a proliferating cell nuclear and nucleolar antigen-like molecule which appears early in the G1-S phase of the cell cycle.

Animals↗
PubMed1987

Novel cell cycle-related nuclear proteins found in rat and human cells with monoclonal antibodies.

Monoclonal antibodies which react specifically with the nuclei of interphase cells recognized three nuclear antigens with molecular weights of 110,000 (p110), 85,000 (p85), and 18,000 (p18). p110 and p85 were found in eight tumor cell lines but were not found in resting lymphocytes. p18 was found in resting lymphocytes as well as the tumor cell lines. Protein p85 appeared in phytohemagglutinin-stimulated lymphocytes in the G1 phase and protein p110 appeared in the S phase. p110 and p85 were localized to the extranucleolar chromatin while p18 was distributed throughout the nucleus and was determined by microscopic and DNase digestion studies to be DNA associated. The anti-p110 antibody recognized a component of the DNA polymerase alpha 2 complex. Three novel nuclear proteins were identified using monoclonal antibodies. Two of these proteins (p110 and p85) are proliferating cell nuclear and nucleolar antigen-like while the third (p18) is not cell cycle dependent.

Animals↗
PubMed1987

Human U3 small nucleolar RNA genes are localized to the nucleoplasm.

U3 RNA, an abundant, conserved, capped, small RNA localized to the nucleolar compartment of eukaryotic cells, its implicated in the processing of pre-ribosomal RNA. The genes for U1 and U2 snRNAs (small nuclear RNAs) are clustered and present in the nucleoplasmic DNA; however, the localization of U3 snRNA genes is not known. DNAs, isolated from HeLa cell nuclei and nucleoli, were hybridized with labeled probes corresponding to the 5'-flanking and the coding regions of the human U3 snRNA gene. The intensity of signals obtained with both the probes were 5-6 fold greater in nuclear DNA, compared to nucleolar DNA. With ribosomal gene probe, the nucleolar DNA had sixfold more intense signal than nuclear DNA. These results indicate that genes for U3 snRNA are in the nucleoplasm. Therefore, U3 snRNA, like 5S ribosomal RNA, appears to be synthesized in the nucleoplasm and transported to the nucleolus.

Cell Compartmentation↗
PubMed1987

Identification and partial characterization of a Mr 40,000 nucleolar antigen associated with cell proliferation.

The present study reports the identification and partial characterization of a novel Mr 40,000 nucleolar antigen (P40) by monoclonal antibodies. Monoclonal antibodies to this protein were obtained when a nucleolar protein extract separated from the immunodominant protein C23 was used to immunize BALB/c mice; 12 hybridoma clones produced antibodies to this protein. P40 was not detected in normal human kidney, liver, and leukocytes but was readily demonstrable in a variety of human malignant tissues. This newly identified P40 antigen differs in its specific nucleolar localization from cyclin (proliferating cell nuclear antigen), a Mr 35,000 antigen which is largely in the nucleoplasm. In addition, cyclin appears in the nucleolus in S-phase; P40 appears in the nucleolus 6 h after refeeding serum-starved HeLa cells.

Animals↗
PubMed1987

Effect of differentiation on the expression of a nucleolar antigen with a molecular weight of 145,000 in HL-60 cells.

Mr 145,000 nucleolar protein antigen (p145) is associated with growing cells (R. L. Ochs et al., J. Cell Biol., 101: 211a, 1985) and has been found in a broad range of human cancers (J. W. Freeman et al., Cancer Res., 46: 3593-3598, 1986). In this study the presence of nucleolar antigen p145 was examined in the human promyelocytic tumor cell line HL-60 which was induced to differentiate by retinoic acid. Differentiation was monitored by morphological changes, [3H]thymidine accumulation, the ability of cells to reduce nitroblue tetrazolium, and cell number. The monoclonal antibody to nucleolar antigen p145 produced bright immunofluorescence in all cycling interphase HL-60 cells; during mitosis only diffuse staining was detected. Nucleolar antigen p145 in HL-60 cells was undetectable after 132 h of treatment with retinoic acid. The absence of nucleolar antigen p145 was associated with an 81% decline in thymidine accumulation and apparent inactivation of ribosomal and nonribosomal DNA transcription as observed by electron microscopy. The loss in expression of the antigen also correlated with increased nitroblue tetrazolium-positive cells, appearance of morphologically distinct myeloid cells, and termination of cell proliferation. These data indicate that the expression of nucleolar antigen p145 occurred in cycling HL-60 cells but not in terminally differentiated noncycling HL-60 cells.

Antibodies, Monoclonal↗